P/B
8,3
Penumbra
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
$12.8B
Market Cap • 10/23/2026
2004
(22 years)
Founded
2015
(11 years ago)
IPO
NYSE
Listing Exchange
United States
Country
Valuation
P/S
8,5
P/EBITDA
60,6
P/OCF
46
P/FCF
59,2
P/E
138
BVPS
38,9
EPS
3,6
Market Cap
Market Cap
12,8B
EV
12,3B
EV/Revenue
8,2
EV/EBITDA
58,5
EV/EBIT
65,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,1%
Total Yield
-0,1%
Payout
0%
Retained Earnings
305,1M
Profitability
Gross Margin
67,8%
EBITDA Margin
14%
EBIT Margin
12,4%
Net Margin
10,7%
D&A/EBITDA
0%
R&D/Revenue
6,1%
Capex/Revenue
4,1%
Capex/D&A
264,9%
Capex/OCF
22,3%
SBC/OCF
21,4%
% PPE
17,1%
% Goodwill
8,4%
ROE
11,4%
ROIC
13,4%
Growth
CAGR Revenue 5Y
17,5%
CAGR Op. Income 5Y
151,2%
CAGR Net Income 5Y
68,1%
CAGR EPS 5Y
40,4%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
5,7
Quick Ratio
3,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!